List All Head and Neck Cancer Trials

Head and Neck Cancer

 

Postoperative Radiation Therapy +/- Cetuximab for Head and Neck Cancer (RTOG 0920)
A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally - Advanced Resected Head and Neck Cancer

Investigator: George Laramore, MD, PhD;   Conditions: Head and Neck Cancer;    Status: Recruiting;   Study ID: NCT00956007

Radiation Therapy w w/o Cetuximab Post Surgery for Locally Advanced Head and Neck Cancer (RTOG 0920)
A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer

Investigator: George E. Laramore, MD, PhD;   Conditions: Head and Neck Cancer;    Status: Recruiting;   Study ID: NCT00956007

Transoral Surgery Followed By Low/Standard-Dose Radiation Therapy w w/o Chemotherapy for HPV Positive Oropharyngeal Cancer (ECOG-ACRIN E3311)
Phase II Randomized Trial of Transoral Surgical Resection Followed by Low-Dose or Standard-Dose IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer

Investigator: Eduardo Mendez, MD;   Conditions: Stage III,IVA, IVB Squamous Cell Carcinoma of the Oropharynx;    Status: Pending;   Study ID: NCT01898494

Transoral Surgery Plus Radiation for HPV Positive Stage III-IVA Oropharyngeal Cancer(9188)
Phase II Randomized Trial of Transoral Surgical Resection followed by Low-dose or Standard-dose IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer

Investigator: Eddie Mendez;   Conditions: Head and Neck Cancer;    Status: Recruiting;   Study ID: NCT01898494

AZD1775, Docetaxel, and Cisplatin Pre-Surgery in Resectable Stage III-IVB Squamous Cell Carcinoma of the Head and Neck (9168)
A Phase I Clinical Trial of AZD1775 in Combination With Neoadjuvant Weekly Docetaxel and Cisplatin Prior to Surgery in Squamous Cell Carcinoma of the Head and Neck (HNSCC)

Investigator: Eduardo Mendez;   Conditions: Stage III-IVB Squamous Cell Carcinoma;    Status: Recruiting;   Study ID: NCT02508246

Pembrolizumab for Recurrent or Metastatic Head and Neck Cancer (20150009)
A Phase III Randomized Trial of MK-3475 (Pembrolizumab) versus Standard Treatment in Subjects with Recurrent or Metastatic Head and Neck Cancer

Investigator: Cristina Rodriguez, MD;   Conditions: Head and Neck Cancer, Squamous Cell;    Status: Recruiting;   Study ID: NCT02252042

MK-3475 Combined with Vorinostat for Metastatic Squamous Cell Head and Neck Cancer (9383)
A single arm Phase I/II study of MK-3475 combined with vorinostat for recurrent unresectable and/or metastatic squamous cell head and neck cancer and recurrent unresectable and/or metastatic salivary gland malignancies

Investigator: Cristina Rodriguez, MD;   Conditions: Head and Neck Cancer;    Status: Recruiting;   Study ID: NCT02538510

MEDI4736 + AZD9150 or AZD5069 for Metastatic Squamous Cell Carcinoma of Head & Neck
A Phase 1b/2, Open-Label, Multicentre Study Assessing the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumour Activity of MEDI4736 in Combination With AZD9150 or AZD5069 in Patients With Advanced Solid Malignancies and Subsequently Comparing AZD9150 and AZD5069 Both as Monotherapy and in Combination With MEDI4736 as Second Line Treatment in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck

Investigator: ;   Conditions: Metastatic Squamous Cell Carcinoma of the Head and Neck;    Status: Pending;   Study ID: NCT02499328